An interventional study of CONEMO App in Depression, Anxiety and Insomnia, sponsored by University of Sao Paulo General Hospital. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Depression with a site in Brazil — 19 open to participants now, 24 under way, 3 of them phase 3. Depression · Brazil.
Among the 100 studies in Depression with a site in Brazil, this one has the largest planned enrollment of the 91 interventional ones that give a count, is one of 8 that started in 2026, is one of 62 with no phase, reaches primary completion later than 13 of the 23 other live ones, and was the 84th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →19 of the 100 studies in Depression with a site in Brazil are open now. Recruiting first, the newest first:
University of Sao Paulo · Sites in Brazil
Ages 18–40 · Women only
Eli Lilly and Company · Sites in Brazil, United States, Australia and 12 more countries
Ages 18–75
Federal University of Minas Gerais · Sites in Brazil
Ages 18+ · Women only
Eli Lilly and Company · Sites in Brazil, United States, Australia and 12 more countries
Ages 18–75
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 15 · Phase 4 3
First in 2005; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12,400 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 80 across the 91 interventional studies, 120 across the 9 observational. Of the 48 that completed or were terminated, 9 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 100 have an industry lead sponsor. The 10 most frequent:
University of Sao Paulo General Hospital is the lead sponsor of 612 studies on the registry; 99 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
University of Sao Paulo General Hospital has 9 studies filed under Depression — fewer than ten, so there is no comparison to draw.
7 of the studies in Depression with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07480668Federal University of Minas GeraisAromatherapy for Mental Health Promotion in IVF Patients | 2026-12 |
| NCT06636006Universidade Federal de GoiasAerobic Exercise Versus Digital Cognitive Behavioral Therapy for Insomnia | 2026-12-30 |
| NCT06692842University of Sao Paulo General HospitalInteractive Technological Intervention to Improve Mental Health Symptoms in Primary Health Care | 2026-12-31 |
| NCT06480019Hospital de Clinicas de Porto AlegreIPT-based Group Intervention by Non-specialist for Improvement of Depressive Symptoms in Community Young Adults in Brazil | 2026-12-31 |
| NCT07925762University of Sao PauloSmartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 100 studies in Depression with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to implement and evaluate a technological intervention called CONEMO to treat depressive symptoms, anxiety, and insomnia in adults who use primary health care services. The effectiveness of this intervention has already been proven in previous research, specifically for depressive symptoms. Implementation will occur in 28 basic health units in the municipalities of Indiatuba and Jaguariúna in the interior of São Paulo.
All eligible residents of the cities will be invited to participate.
A type III hybrid implementation and effectiveness study, with a mixed-method explanatory sequential design consisting of two distinct stages: the first quantitative, followed by qualitative. The method is indicated when the researcher wishes to use qualitative data to help interpret and explain the initial quantitative findings and deepen them. The elements of both methods are analyzed separately and then merged, looking for convergences, divergences, contradictions, or relationships between the two databases.
The qualitative data will help to interpret, explain and deepen the quantitative findings. The guidelines of the Consolidated Criteria for Reporting Qualitative Research (COREQ) will be followed, a 32-item instrument that guides the conduct of the interview and analysis of qualitative data, also validated in Portuguese in Brazil.
Study site The study will be carried out in 28 Basic Health Units (UBS) in two municipalities in the interior of São Paulo, Indaiatuba and Jaguariúna, located approximately 100 km from the capital São Paulo, in the state of São Paulo, Brazil.
Study population - stakeholder groups Patients/service users - user category Our study population will be made up of adult individuals (18 years or older) who live in the municipality of Indaiatuba or Jaguariúna and attend the UBS and who show significant symptoms of depression, anxiety or insomnia.
Health professionals, service managers and local managers - professional categories Adults (18 years or older) from the groups of interest will also participate in the study: health professionals from the UBS in the municipalities of Jaguariúna and Indaiatuba, service managers, health department managers, or primary care and mental health coordinators. We consider these individuals to be the main stakeholders, in addition to the users and main participants in the research, in the unfolding of the CONEMO intervention implementation study.
Study population
User participants - quantitative study:
All individuals screened at the cities' UBSs with positive symptoms for insomnia, anxiety or depression.
Participants - users, health professionals and managers - barriers and facilitators - qualitative study The focus groups in this study will be divided into categories of participants selected from each UBS involved. The categories of participation will be users, technical health professionals, senior health professionals and the manager of each participating unit. Simple randomization will be carried out to select one participant from each category among users and health professionals. With regard to managers, the invitation will be extended to all managers of the participating health units. These focus groups will be conducted separately for each category of participants at the end of three months from the start of the study. It is important to note that the users included in the focus groups may be at different stages of using the application. Specific guiding scripts will be used to collect the qualitative data, which will be drawn up after analyzing the quantitative data.
Research Steering Committee - CGP This committee plays a crucial role in monitoring and evaluating the outcomes of the implementation of interventions and policies. Composed of a multidisciplinary team, including academic researchers, local managers, and service workers, the committee facilitates the active participation of all stakeholders in the research process. Its main objective is to ensure that contextual elements are taken into account and that real conditions are understood and worked on. The committee meets regularly to discuss the research progress, evaluate the strategies' implementation and provide constructive feedback. This participatory and collaborative approach helps to identify and overcome possible challenges in implementation, thus promoting the effectiveness and sustainability of the mental health policies implemented. The CGP will also include users of municipal health services.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CONEMO is a low-intensity psychoeducational program which is made available to users via smartphones compatible with Android or iOS systems. At the same time, the designed healthcare professional use a tablet to monitor user adherence to the intervention. CONEMO comprise seven weekly modules, totally self-guides.
Device: CONEMO App
The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.
Proportion of participants who have 'recovered' from depressive symptoms (PHQ-9 < 10)
Patient Health Questionnaire-9 (PHQ-9) is a questionnaire to access the severity of participants' depressive symptoms. The PHQ-9 score varies according to the severity of the symptoms and is classified as follows: no depression (0 to 4), mild symptoms (5 to 9), moderate symptoms (10 to 14), moderately severe symptoms (15 to 19) and severe symptoms (20 to 27). A cut-off point of 10 is suggested to indicate the presence of significant depressive symptoms.
Time frame: 3 months
Proportion of participants who have 'recovered' from anxiety (GAD-7< 10)
General Anxiety Disorder-7 (GAD-7) scale, which measures common symptoms associated with generalized anxiety disorder in the last two weeks. Each of the scale's seven items ranges from 0 ('not at all') to 3 ('almost every day'), resulting in a total score ranging from 0 to 21. A suggested cut-off point of more than 10 points indicates the presence of anxiety.
Time frame: 3 months
Proportion of participants who have 'recovered' from insomnia (IGI<8)
Insomnia Severity Index (IGI) is a retrospective instrument that assesses the last month and is made up of seven items that explore various aspects of sleep, including difficulties initiating or maintaining sleep, early morning awakening, satisfaction with sleep, daytime impairment, perception of sleep problems by other people, and concern about sleep problems. Respondents use a Likert scale ranging from 0 (no severity) to 4 (high severity), resulting in a total score ranging from 0 to 28. This score is classified as follows: no insomnia (0 to 7), mild insomnia (8 to 14), moderate insomnia (15 to 21) and severe insomnia (22 to 28
Time frame: 3 months
Social Support Assessment:
The participant's relationships with other people, i.e. whether they have a support network, will be explored throught a questionnaire
Time frame: 3 months and 6 months
Quality of Life
The level 3 version of the 5-item EUROQol questionnaire (EQ 5D-3L), which covers five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with three levels of severity, will be used to access changes in quality of life.
Time frame: 3 months and 6 months
Daily Activity Level:
Through the short form of the Behavioral Activation Scale for Depression (BADS). The BADS is a 9-item scale that measures the frequency of activation and avoidance behaviors that are hypothetically fundamental to the mechanisms of depression. This instrument will only be applied to participants in the depression journey.
Time frame: 3 months and 6 months
Plan to share: Yes — The data will be shared on the OSF platform after the study is completed, upon request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: After study completion and publication of the results
Access criteria: Upon request from others researchers
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sao Paulo General Hospital →